Luis Diaz

Luis A. Diaz, Jr., M.D. is a recently elected member of the Board of Directors at Quest Diagnostics, joining in May 2023.12 His appointment expanded the company's board to 10 members.1

Professional Background

Dr. Diaz, 52 years old, is a distinguished oncologist and researcher with a focus on solid tumor oncology.1 He currently serves as the Head of the Division of Solid Tumor Oncology at Memorial Sloan Kettering Cancer Center, a position he has held since December 2016.13

Academic and Research Achievements

Dr. Diaz's career is marked by significant contributions to cancer research and treatment:

• He provided the first definitive evidence for using circulating tumor DNA as a cancer biomarker for screening, monitoring, and detection of occult disease.1
• He discovered the therapeutic link between immunotherapy and cancer genetics in patients with mismatch repair deficient tumors.1
• His research led to the first tumor agnostic FDA approval for tumors with a specific genetic lesion.1
• In 2022, he published a cancer study that resulted in a 100% complete remission rate.1

Entrepreneurial Ventures

Dr. Diaz has demonstrated his entrepreneurial spirit by founding several biotechnology companies, including:

• Epitope
• Inostics
• PapGene (Thrive)
• Personal Genome Diagnostics, Inc.1

Education and Training

• Undergraduate and medical degrees from the University of Michigan
• Completed medical training at Johns Hopkins1

Honors and Appointments

In recognition of his contributions to the field of oncology, Dr. Diaz was appointed by President Biden in 2021 to the National Cancer Advisory Board of the National Institutes of Health.1

Dr. Diaz's expertise in advanced oncology research, patient care, and entrepreneurship makes him a valuable addition to Quest Diagnostics' Board of Directors, particularly as the company expands its presence in molecular oncology and genomics.1